Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ruth Ramos-Díaz"'
Autor:
María Micaela Viña Romero, Ruth Ramos Díaz, Betel Del Rosario García, Alejandro Jiménez Sosa, José Alberto Morales Barrios, Juana M Oramas Rodríguez, Gloria Julia Nazco Casariego, Fernando Gutiérrez Nicolás
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:530-534
Introduction Patient-reported outcomes (PROs) use, via a computer registry, allows patients to report their symptoms enabling the detection of early signs of progression of the disease. For such a record, the patient needs to show certain skills in n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe4230479efb44fdb6d0a7ea3268d04
https://doi.org/10.1177/1078155221996041
https://doi.org/10.1177/1078155221996041
Autor:
Silvia, Peña-Cabia, Ana, Royuela-Vicente, Ruth, Ramos-Díaz, Fernando, Gutiérrez-Nicolás, Benito, García-Díaz, Ana, López-Martín
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(1)
There is limited scientific evidence on the cetuximab exposure-response relationship and no concentration threshold has been associated with optimal disease control. The aims were to assess, in a real-life setting, the relationship between steady sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e1705475e121d97c7518620bb7a74968
https://pubmed.ncbi.nlm.nih.gov/35379088
https://pubmed.ncbi.nlm.nih.gov/35379088
Autor:
Betel Del Rosario García, Jonathan González García, Fernando Gutiérrez Nicolás, Iris González García, Ruth Ramos Díaz, Sunil Lakhwani Lakhwani, Ivette Mourani Padrón, María Micaela Viña Romero, Gloria Julia Nazco Casariego
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 29(1)
Introduction The addition of imatinib to the therapeutic arsenal for chronic myeloid leukaemia (CML) has changed the natural course of the disease, in such a way that it is now considered a chronic pathology. However, to achieve therapeutic success,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caff4d693a46c2bf579292df9a07e7d5
https://pubmed.ncbi.nlm.nih.gov/34661491
https://pubmed.ncbi.nlm.nih.gov/34661491
Autor:
Betel Del Rosario García, José Alberto Morales Barrios, Josefina Cruz Jurado, Ruth Ramos Díaz, María Micaela Viña Romero, Ivette Mourani Padrón, Gloria Julia Nazco Casariego, Fernando Gutiérrez Nicolás
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522211437
Objectives Imatinib is the first therapeutic option for the treatment of unresectable or metastatic gastrointestinal stromal tumours. Previous studies have shown an improvement in patient survival rates following the use of imatinib. Nevertheless, ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987742950605244103e1707b70d5a505
https://doi.org/10.1177/10781552221143788
https://doi.org/10.1177/10781552221143788
Autor:
Hector Gonzalez-Mendez, Fernando Gutiérrez-Nicolás, Javier F Merino-Alonso, Macarena Gonzalez-Cruz, Ivette Mourani-Padron, Ruth Ramos-Díaz, Jesica Diaz-Vera, Gloria Julia Nazco-Casariego, Micaela M ViÑa-Romero
Publikováno v:
In Vivo
Background/aim L-Asparaginase (L-ASNase) is used as a tumor-inhibitory drug on paediatric acute lymphoblastic leukemia (ALL). ERW-ASNase is commercialised as a lyophilized powder stable only for 8 hours once reconstituted and, consequently, the lefto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::902cfda927c2070fcd13661e60157ccc
https://doi.org/10.21873/invivo.12055
https://doi.org/10.21873/invivo.12055
Autor:
Jonathan González García, Ruth Ramos Díaz, Isaac Ceballos Lenza, Fernando Gutiérrez Nicolás, Ivette Mourani Padrón
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(6)
Introduction Trastuzumab is a monoclonal antibody which could induce the activation of a humoral immune response generating anti-drug antibodies (ADAs). Such response depends of the protein nature and the route of administration (intravenous or subcu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be5717b1f150f4b0a33f92a204b0983c
https://pubmed.ncbi.nlm.nih.gov/32873135
https://pubmed.ncbi.nlm.nih.gov/32873135
Autor:
Matías Llabres Martinez, José Norberto Batista López, Marta Llanos Muñoz, Ruth Ramos Díaz, Isaac Ceballos Lenza, Josefina Cruz Jurado, Alejandro Jiménez Sosa, María Micaela Viña Romero, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Jonathan González García
Publikováno v:
The Annals of pharmacotherapy. 54(8)
Background: Subcutaneous trastuzumab (T-SC) administration does not allow the historical target concentration of 20 µg/mL for efficacy to be reached, from the start of treatment in patients with a body mass index (BMI) >30 kg/m2. Objectives: To anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d96627d9c10c9787df91a942168b078
https://pubmed.ncbi.nlm.nih.gov/31971005
https://pubmed.ncbi.nlm.nih.gov/31971005
Efecto de los polimorfismos en UGT, SLCO, ABCB y ABCC en la toxicidad del tratamiento con irinotecán
Autor:
Ruth Ramos Díaz, Braulio Martin Calero, Marta Llanos Muñoz, Sara García Gil, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, María Micaela Viña Romero, José A. Pérez
Publikováno v:
Medicina Clínica. 151:425-430
Resumen Antecedentes y objetivos Evaluar la relacion entre la presencia de polimorfismos en los genes implicados en la farmacodinamia del irinotecan (UGT1A, SLCO1B1, ABCB1 y ABCC2) y la seguridad asociada al mismo en el tratamiento del cancer colorre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::675b09fd2c9ea7b2aea91a0a5eb2e803
https://doi.org/10.1016/j.medcli.2018.01.016
https://doi.org/10.1016/j.medcli.2018.01.016
Autor:
Marta Llanos Muñoz, Ruth Ramos Díaz, José A. Pérez, Sara García Gil, María Micaela Viña Romero, Fernando Gutiérrez Nicolás, Gloria Julia Nazco Casariego, Braulio Martin Calero
Publikováno v:
Medicina Clínica (English Edition). 151:425-430
Background and objectives Evaluate the relationship between the presence of polymorphisms in genes involved in the pharmacodynamics of irinotecan (UGT1A, SLCO1B1, ABCB1 and ABCC2) and the safety of irinotecan in the treatment of metastatic colorectal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f35b18ae2519f74c5f6b703a7ec95823
https://doi.org/10.1016/j.medcle.2018.01.038
https://doi.org/10.1016/j.medcle.2018.01.038
Autor:
Isaac Ceballos Lenza, Ruth Ramos Díaz, Matías Llabres Martinez, Jonathan González García, José Norberto Batista López, Gloria Julia Nazco Casariego, Fernando Gutiérrez Nicolás
Publikováno v:
Annals of Pharmacotherapy. 51:976-980
Background: Plasma concentrations of trastuzumab min) of 20 µg/mL after first drug administration, established as therapeutically effective in clinical trials. The secondary objective was to identify the physiological and anthropometric characterist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcebb7e2b9630ff545048ab7b6537d45
https://doi.org/10.1177/1060028017715727
https://doi.org/10.1177/1060028017715727